Your browser doesn't support javascript.
loading
Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity / Avaliação dos resultados após 2 anos de injeção de bevacizumab intravítreo para retinopatia da prematuridade posterior agressiva
Gunay, Murat; Celik, Gokhan; Gunay, Betul Onal; Aktas, Alev; Karatekin, Guner; Ovali, Fahri.
Affiliation
  • Gunay, Murat; Zeynep Kamil Maternity and Children’s Disease Training and Research Hospital. ROP Training and Treatment Center. Department of Ophthalmology. Istanbul. TR
  • Celik, Gokhan; Zeynep Kamil Maternity and Children’s Disease Training and Research Hospital. ROP Training and Treatment Center. Department of Ophthalmology. Istanbul. TR
  • Gunay, Betul Onal; Zeynep Kamil Maternity and Children’s Disease Training and Research Hospital. ROP Training and Treatment Center. Department of Ophthalmology. Istanbul. TR
  • Aktas, Alev; Zeynep Kamil Maternity and Children’s Disease Training and Research Hospital. ROP Training and Treatment Center. Department of Ophthalmology. Istanbul. TR
  • Karatekin, Guner; Zeynep Kamil Maternity and Children’s Disease Training and Research Hospital. ROP Training and Treatment Center. Department of Ophthalmology. Istanbul. TR
  • Ovali, Fahri; Zeynep Kamil Maternity and Children’s Disease Training and Research Hospital. ROP Training and Treatment Center. Department of Ophthalmology. Istanbul. TR
Arq. bras. oftalmol ; Arq. bras. oftalmol;78(5): 300-304, Sep.-Oct. 2015. tab, ilus
Article de En | LILACS | ID: lil-761523
Bibliothèque responsable: BR1.1
ABSTRACT
ABSTRACT

Purpose:

To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP).

Methods:

Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Group II included infants who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of anisometropia and strabismus were assessed at follow-up examinations.

Results:

Group I included 48 eyes of 25 infants (11 males) with a mean gestational age (GA) of 26.40 ± 1.82 weeks and a mean birth weight (BW) of 901.40 ± 304.60 g. Group II included 30 eyes of 15 infants (6 males) with a mean GA of 27.30 ± 1.82 weeks and a mean BW of 941.00 ± 282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). Refractive errors were significantly less myopic in group I (0.42 ± 3.42 D) than in group II (-6.66 ± 4.96 D) at 2 years (P=0.001). Significantly higher rates of anisometropia and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively).

Conclusions:

The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for patients treated with IVB, and this needs to be better evaluated in future prospective studies.
RESUMO
RESUMO

Objetivo:

Avaliar a evolução de 2 anos em crianças que receberam bevacizumab intravítreo (IVB) como monoterapia para retinopatia da prematuridade posterior agressiva (APROP).

Métodos:

Arquivos médicos de 40 crianças foram revisados retrospectivamente. Grupo I incluiu as crianças que tiveram injeções IVB para APROP. Grupo II foi composto por crianças que se submeteram a tratamento a laser para APROP. Os resultados anatômicos e refracionais, presença de anisometropia e estrabismo foram avaliados durante exames de acompanhamento.

Resultados:

Grupo I incluiu 48 olhos de 25 crianças (11 do sexo masculino) com média de idade gestacional (GA) de 26,40 ± 1,82 semanas, e média de peso ao nascimento (BW) de 901,40 ± 304,60 g. Grupo II incluiu 30 olhos de 15 crianças (6 do sexo masculino) com GA de 27,30 ± 1,82 semanas e BW de 941,00 ± 282,48 g. GA, BW e distribuição por sexo foram semelhantes entre os grupos (p=0,187, p=0,685, p=1,000, respectivamente). Nenhuma anormalidade anatômica foi observada em ambos os grupos. Erro refrativo foi significativamente menos míope no grupo I (0,42 ± 3,42 D) do que o grupo II (-6,66 ± 4,96 D) em exames aos 2 anos (p=0,001). Houve significativamente maior taxa de anisometropia e estrabismo no grupo II em relação ao grupo I (p=0,009, p=0,036, respectivamente).

Conclusões:

O estudo demonstrou que a monoterapia IVB pode ser útil no tratamento de APROP. A diminuição da incidência de resultados refracionais e funcionais desfavoráveis precoces no grupo IVB em comparação com o grupo do laser mostraram um benefício potencial para os pacientes tratados com IVB, e isto tem de ser melhor avaliado em estudos prospectivos no futuro.
Sujet(s)
Mots clés

Texte intégral: 1 Indice: LILACS Sujet Principal: Rétinopathie du prématuré / Inhibiteurs de l'angiogenèse / Injections intravitréennes / Bévacizumab Type d'étude: Etiology_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites du sujet: Female / Humans / Infant / Male langue: En Texte intégral: Arq. bras. oftalmol Thème du journal: OFTALMOLOGIA Année: 2015 Type: Article

Texte intégral: 1 Indice: LILACS Sujet Principal: Rétinopathie du prématuré / Inhibiteurs de l'angiogenèse / Injections intravitréennes / Bévacizumab Type d'étude: Etiology_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites du sujet: Female / Humans / Infant / Male langue: En Texte intégral: Arq. bras. oftalmol Thème du journal: OFTALMOLOGIA Année: 2015 Type: Article